FR11C0042I1 - - Google Patents

Info

Publication number
FR11C0042I1
FR11C0042I1 FR11C0042C FR11C0042I1 FR 11C0042 I1 FR11C0042 I1 FR 11C0042I1 FR 11C0042 C FR11C0042 C FR 11C0042C FR 11C0042 I1 FR11C0042 I1 FR 11C0042I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23262376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0042(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR11C0042I1 publication Critical patent/FR11C0042I1/fr
Application filed filed Critical
Application granted granted Critical
Publication of FR11C0042I2 publication Critical patent/FR11C0042I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • B65D81/3216—Rigid containers disposed one within the other
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
FR11C0042C 2001-09-21 2011-09-27 Composes contenant du lactame et leurs derives en tant qu'inhibiteurs du facteur xa Active FR11C0042I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32416501P 2001-09-21 2001-09-21
PCT/US2002/029491 WO2003026652A1 (fr) 2001-09-21 2002-09-17 Composes contenant du lactame et leurs derives en tant qu'inhibiteurs du facteur xa

Publications (2)

Publication Number Publication Date
FR11C0042I1 true FR11C0042I1 (fr) 2011-04-11
FR11C0042I2 FR11C0042I2 (fr) 2013-01-11

Family

ID=23262376

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0042C Active FR11C0042I2 (fr) 2001-09-21 2011-09-27 Composes contenant du lactame et leurs derives en tant qu'inhibiteurs du facteur xa

Country Status (40)

Country Link
US (11) US7338963B2 (fr)
EP (2) EP1427415B1 (fr)
JP (2) JP4249621B2 (fr)
KR (2) KR100909141B1 (fr)
CN (5) CN1578660B (fr)
AR (2) AR037092A1 (fr)
AT (2) ATE439360T1 (fr)
AU (2) AU2002341693B2 (fr)
BE (1) BE2011C034I2 (fr)
BR (1) BRPI0212726B8 (fr)
CA (2) CA2461202C (fr)
CH (1) CH1427415H1 (fr)
CL (1) CL2008002717A1 (fr)
CO (1) CO5560567A2 (fr)
CY (2) CY1110509T1 (fr)
DE (2) DE60233335D1 (fr)
DK (1) DK1427415T3 (fr)
ES (1) ES2329881T3 (fr)
FR (1) FR11C0042I2 (fr)
GE (1) GEP20074098B (fr)
HK (1) HK1061973A1 (fr)
HR (2) HRP20040280B1 (fr)
HU (2) HU228195B1 (fr)
IL (3) IL160693A0 (fr)
IS (2) IS3006B (fr)
LT (1) LTPA2011012I1 (fr)
LU (1) LU91888I2 (fr)
ME (2) ME00090B (fr)
MX (1) MXPA04002526A (fr)
MY (1) MY137830A (fr)
NO (4) NO328558B1 (fr)
NZ (1) NZ531616A (fr)
PL (2) PL204653B1 (fr)
PT (1) PT1427415E (fr)
RS (2) RS51444B (fr)
RU (2) RU2345993C2 (fr)
SI (1) SI1427415T1 (fr)
UA (1) UA78232C2 (fr)
WO (1) WO2003026652A1 (fr)
ZA (1) ZA200402184B (fr)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
AU2002328596B2 (en) * 2001-08-09 2007-09-20 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
PL204653B1 (pl) 2001-09-21 2010-01-29 Bristol Myers Squibb Co Pochodna pirazolo [3, 4-c] pirydyny, jej zastosowanie i kompozycja farmaceutyczna
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TW200303201A (en) 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
US20060229335A1 (en) * 2002-12-24 2006-10-12 Bradley Teegarden Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
WO2004058715A1 (fr) * 2002-12-25 2004-07-15 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
JP4630267B2 (ja) * 2002-12-25 2011-02-09 第一三共株式会社 ジアミン誘導体
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
US7205318B2 (en) * 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
CN1894234A (zh) 2003-03-25 2007-01-10 武田药品工业株式会社 二肽基肽酶抑制剂
BRPI0412263B1 (pt) * 2003-07-22 2019-10-15 Arena Pharmaceuticals, Inc. Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MXPA06001601A (es) 2003-08-13 2006-08-25 Takeda Pharmaceutical Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa.
WO2005026148A1 (fr) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Inhibiteurs de la dipeptidylpeptidase
TW200512181A (en) * 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
US20050119266A1 (en) * 2003-10-01 2005-06-02 Yan Shi Pyrrolidine and piperidine derivatives as factor Xa inhibitors
US7115646B2 (en) * 2003-10-08 2006-10-03 Bristol Myers Squibb, Co. Cyclic diamines and derivatives as factor Xa inhibitors
ES2535842T3 (es) 2004-02-24 2015-05-18 Sumitomo Chemical Company, Limited Composición insecticida
US7371743B2 (en) 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
CA2559038C (fr) * 2004-03-23 2013-09-10 Arena Pharmaceuticals, Inc. Methodes de preparation de n-aryl-n'-[3-(1h-pyrazol-5-yl) phenylurees] substituees et leurs intermediaires
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
WO2005118555A1 (fr) 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
WO2006019965A2 (fr) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Inhibiteurs de la dipeptidyl peptidase
US7304157B2 (en) 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7388096B2 (en) 2004-09-28 2008-06-17 Bristol-Myers Squibb Company Crystalline forms of a factor Xa inhibitor
US7396932B2 (en) 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
CN101068812B (zh) * 2004-09-28 2010-09-29 布里斯托尔-迈尔斯斯奎布公司 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮的有效合成
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
PE20061130A1 (es) * 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
DE102004059219A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Pyrazindicarbonsäureamide und ihre Verwendung
AR053990A1 (es) * 2004-12-15 2007-05-30 Bristol Myers Squibb Co Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion.
WO2006068978A2 (fr) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Inhibiteurs de dipeptidyle peptidase
WO2006078621A2 (fr) 2005-01-19 2006-07-27 Bristol-Myers Squibb Company Composes heteroaryle tenant lieu d'inhibiteurs du recepteur p2y1
US20060160841A1 (en) * 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
JP2006298909A (ja) * 2005-03-25 2006-11-02 Tanabe Seiyaku Co Ltd 医薬組成物
KR20080027890A (ko) 2005-06-27 2008-03-28 브리스톨-마이어스 스큅 컴퍼니 혈전성 증상의 치료에 유용한 ｐ2ｙ1 수용체의 ｎ-연결헤테로시클릭 길항제
EP1899299B1 (fr) 2005-06-27 2010-10-20 Bristol-Myers Squibb Company Antagonistes cycliques a liaison c du recepteur p2y1, utiles pour traiter des etats pathologiques thrombotiques
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7816382B2 (en) 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
WO2007033350A1 (fr) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete
EP1924567B1 (fr) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidylpeptidase
TW200734304A (en) 2005-11-08 2007-09-16 Astellas Pharma Inc Benzene derivative or salt thereof
WO2007087246A2 (fr) * 2006-01-24 2007-08-02 Merck & Co., Inc. Inhibition de la tyrosine kinase jak2
EP1978958A4 (fr) * 2006-01-24 2009-12-02 Merck & Co Inc Inhibition de la tyrosine kinase ret
EA016675B1 (ru) 2006-05-18 2012-06-29 Арена Фармасьютикалз, Инк. Способы получения фенилпиразолов и кристаллическая форма производного фенилпиразола
WO2007136703A1 (fr) 2006-05-18 2007-11-29 Arena Pharmaceuticals, Inc. Amines primaires et dérivés de celles-ci utilisés en tant que modulateurs du récepteur de la sérotonine 5-ht2a utiles pour traiter des troubles associés à ce récepteur
EP3395816A1 (fr) * 2006-05-18 2018-10-31 Arena Pharmaceuticals, Inc. Éthers, amines secondaires et leurs dérivés en tant que modulateurs du récepteur de la sérotonine 5-ht2a utiles pour le traitement de troubles associés
DE102006025315A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Tetrahydro-pyrrolopyridin-, Tetrahydro-pyrazolopyridin-, Tetrahydro-imidazopyridin- und Tetrahydro-triazolopyridin-Derivate und ihre Verwendung
DE102006025314A1 (de) 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TWI415845B (zh) * 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CN101605779B (zh) 2006-12-15 2013-11-20 百时美施贵宝公司 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
CN101663293B (zh) 2007-04-23 2013-07-31 塞诺菲-安万特股份有限公司 作为p2y12拮抗剂的喹啉-甲酰胺衍生物
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007032344A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Prodrug-Derivate von 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-carboxamid
WO2009023253A2 (fr) 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. Dérivés d'imidazo[l,2-α]pyridine utilisés comme modulateurs du récepteur sérotoninergique 5-ht2a dans le traitement des troubles qui lui sont associés
EP2238128B1 (fr) 2007-12-26 2012-08-22 Sanofi Pyrazole-carboxamides hétérocycliques utilisés en tant qu'antagonistes du récepteur p2y12
WO2009123714A2 (fr) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Procédés de préparation de dérivés de pyrazole utiles comme modulateurs du récepteur de la sérotonine 5-ht<sb>2a</sb>
CN102066385A (zh) * 2008-04-30 2011-05-18 弗雷德里克·阿尔姆奎斯特 新的拟肽化合物
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
DK2364142T3 (en) * 2008-10-28 2018-04-30 Arena Pharm Inc COMPOSITIONS OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USED FOR TREATMENT OF DISEASES RELATED TO THE RECEPTOR
WO2011075596A1 (fr) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Formes cristallines de certains dérivés de 3-phényl-pyrazole, modulatrices du récepteur 5-ht2a de la sérotonine, utiles pour le traitement de troubles y étant associés
AU2011215898B2 (en) 2010-02-11 2016-08-11 Bristol-Myers Squibb Company Macrocycles as Factor XIa inhibitors
HUE027168T2 (en) * 2010-02-25 2016-10-28 Bristol Myers Squibb Co Apixaban formulations
CA2824885A1 (fr) 2011-01-19 2012-07-26 Bayer Intellectual Property Gmbh Proteines de liaison a des inhibiteurs de facteurs de coagulation
US8884016B2 (en) 2011-06-10 2014-11-11 Dipharma Francis S.R.L. Apixaban preparation process
ITMI20111047A1 (it) * 2011-06-10 2012-12-11 Dipharma Francis Srl Forma cristallina di apixaban
EP2554159A1 (fr) 2011-08-04 2013-02-06 ratiopharm GmbH Formes pharmaceutiques comportant de l'apixaban et améliorant d'uniformité de contenu
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
SG11201401384UA (en) 2011-10-14 2014-09-26 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CN103987697B (zh) 2011-10-14 2017-04-26 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
ES2579832T3 (es) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
CN202271910U (zh) * 2011-10-31 2012-06-13 潘磊 一种多功能汽车后视镜
CN103242310A (zh) * 2012-02-10 2013-08-14 苏州迈泰生物技术有限公司 吡唑并吡啶酮类化合物及其在制备抗凝血药物中的用途
MX346147B (es) 2012-03-07 2017-03-09 Inst Of Cancer Research: Royal Cancer Hospital (The) Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.
EP2832734A4 (fr) * 2012-03-28 2015-08-26 Takeda Pharmaceutical Composé hétérocyclique
CA2873949A1 (fr) 2012-05-24 2013-11-28 Ratiopharm Gmbh Formes de dosage comprenant apixaban et un agent de formation de matrice
US9409908B2 (en) 2012-08-03 2016-08-09 Bristol-Myers Squibb Company Dihydropyridone p1 as factor XIa inhibitors
BR112015002293A2 (pt) 2012-08-03 2017-07-04 Bristol Myers Squibb Co di-hidropiridona pi como inibidores do fator xia
WO2014044107A1 (fr) * 2012-09-18 2014-03-27 上海恒瑞医药有限公司 Dérivé de pyrazol[3,4-c] pyridine, son procédé de préparation et son utilisation comme médicament
CN104736142B (zh) * 2012-09-26 2020-03-03 百时美-施贵宝控股爱尔兰无限公司 阿哌沙班液体制剂
WO2014056434A1 (fr) * 2012-10-10 2014-04-17 Sunshine Lake Pharma Co., Ltd. Forme cristalline et forme amorphe de l'apixaban et leur préparation
CA2890002A1 (fr) 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Derives contenant un sulfonamide cyclique en tant qu'inhibiteurs de la voie de signalisation hedgehog
CZ304846B6 (cs) 2012-11-13 2014-12-03 Zentiva, K.S. Způsob přípravy APIXABANU
EP2752414A1 (fr) 2013-01-04 2014-07-09 Sandoz AG Forme cristalline d'apixaban
EP2948187B1 (fr) * 2013-01-24 2019-10-16 Universita' Degli Studi di Bari Hétérocycles et leurs analogues radiomarqués utiles en tant qu'inhibiteurs sélectifs de cox-1
CN103539795A (zh) * 2013-03-18 2014-01-29 齐鲁制药有限公司 阿哌沙班的多晶型及其制备方法
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
CN104109165A (zh) * 2013-04-19 2014-10-22 四川海思科制药有限公司 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用
CZ2013305A3 (cs) 2013-04-23 2014-11-05 Zentiva, K.S. Nové krystalické formy APIXABANU a způsob jejich přípravy
US20160113912A1 (en) 2013-06-18 2016-04-28 Cadila Healthcare Limited An improved process for the preparation of apixaban and intermediates thereof
CN104370902A (zh) * 2013-08-12 2015-02-25 药源药物化学（上海）有限公司 一种阿哌沙班新晶型及其制备方法
CA2922469A1 (fr) 2013-09-11 2015-03-19 Institute Of Cancer Research: Royal Cancer Hospital (The) Composes de 3-arylisoquinol-1-one 5-substituee et leur utilisation therapeutique
CN104650072B (zh) * 2013-11-18 2016-03-16 成都苑东生物制药股份有限公司 一种吡啶类衍生物
CN105829305B (zh) 2013-12-18 2018-11-30 葛兰素史密斯克莱知识产权发展有限公司 Nrf2调节剂
CN116987080A (zh) 2014-01-31 2023-11-03 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
NO2760821T3 (fr) 2014-01-31 2018-03-10
CN103923080B (zh) * 2014-04-04 2016-06-22 苏州景泓生物技术有限公司 一种制备抗血栓药物阿哌沙班的方法
CN105085515B (zh) * 2014-05-22 2019-02-01 华北制药股份有限公司 作为凝血因子Xa抑制剂的酰肼类化合物
KR102412045B1 (ko) * 2014-05-22 2022-06-22 놀스 차이나 파마수티칼 컴퍼니., 엘티디. 혈액응고인자 Xa 억제제로서의 히드라지드 화합물
WO2015177801A1 (fr) * 2014-05-23 2015-11-26 Symed Labs Limited Nouveau procede pour la preparation d'un compose contenant du lactame
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
HU231122B1 (hu) 2014-08-06 2020-11-30 Egis Gyógyszergyár Zrt Eljárás apixaban előállítására
JP6667507B2 (ja) * 2014-09-02 2020-03-18 石薬集団中奇制薬技術（石家庄）有限公司 ピラゾロ［３，４−ｃ］ピリジン誘導体
CN104311557B (zh) * 2014-09-19 2016-01-06 广东东阳光药业有限公司 含有二酮取代基的吡唑并哌啶酮类化合物及其组合物及用途
CN104277041B (zh) * 2014-09-19 2016-01-06 广东东阳光药业有限公司 含取代甲基的芳香环取代基的吡唑并哌啶酮类化合物及其组合物及用途
CN104277039B (zh) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 含有取代丁炔基的吡唑并哌啶酮类化合物及其组合物及用途
CN104311541B (zh) * 2014-09-19 2017-12-05 广东东阳光药业有限公司 含取代的甲酮的吡唑类化合物及其组合物及用途
CN104277040B (zh) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 含有酰基哌嗪酮取代基的吡唑并哌啶酮类化合物及其组合物及用途
CN104327074B (zh) * 2014-09-19 2016-01-06 广东东阳光药业有限公司 含有内酰胺取代基的吡唑并哌啶酮类化合物及其组合物及用途
CN104311555B (zh) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 吡唑并哌啶酮类化合物及其组合物及用途
NO2721243T3 (fr) 2014-10-01 2018-10-20
HU230991B1 (hu) 2014-11-19 2019-08-28 Egis Gyógyszergyár Zrt. Eljárás és köztitermék apixaban előállítására
US9603846B2 (en) 2014-11-25 2017-03-28 Cadila Healthcare Limited Process for the preparation of apixaban
CN104513239B (zh) * 2014-12-10 2017-08-22 沈阳药科大学 吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用
CN104530080B (zh) * 2014-12-10 2017-01-11 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
EP3078378B1 (fr) 2015-04-08 2020-06-24 Vaiomer Utilisation d'inhibiteurs du facteur xa destinés à réguler la glycémie
CN104892601B (zh) * 2015-06-09 2017-09-19 江苏中邦制药有限公司 一种抗血栓药物阿哌沙班的制备方法
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
CN108112251B (zh) 2015-06-15 2021-03-05 葛兰素史克知识产权发展有限公司 Nrf2调节剂
EP3307729B1 (fr) 2015-06-15 2020-09-02 GlaxoSmithKline Intellectual Property Development Limited Régulateurs de nrf2
JP6742348B2 (ja) 2015-06-19 2020-08-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としてのジアミド大員環
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
CN114874222A (zh) 2015-07-29 2022-08-09 百时美施贵宝公司 携带非芳族p2,基团的因子xia新大环
US10336730B2 (en) 2015-08-05 2019-07-02 Bristol-Myers Squibb Company Substituted glycine derived FXIA inhibitors
EA202191548A1 (ru) 2015-10-01 2021-09-02 Байокрист Фармасьютикалз, Инк. Ингибиторы плазменного калликреина человека
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
WO2017088841A1 (fr) 2015-11-26 2017-06-01 Zentiva, K.S. Préparation d'une forme médicamenteuse contenant de l'apixaban amorphe
EP3423458A1 (fr) 2016-03-02 2019-01-09 Bristol-Myers Squibb Company Macrocycles diamide présentant une activité inhibitrice du facteur xia
WO2017221209A1 (fr) 2016-06-23 2017-12-28 Lupin Limited Formulations pharmaceutiques d'apixaban
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CA3039203A1 (fr) * 2016-10-03 2018-04-12 Sigilon Therapeutics, Inc. Composes, dispositifs et utilisations associees
CN107064367B (zh) * 2017-04-20 2019-09-13 青岛理工大学 一种环境水样中四种杂环类农药的分析检测方法
CN106940355B (zh) * 2017-04-24 2018-08-24 中国药科大学 一种布洛芬、其钠盐及其制剂有关物质的检测方法
WO2019123194A1 (fr) * 2017-12-20 2019-06-27 Pi Industries Ltd. Anthranilamides, leur utilisation en tant qu'insecticides et leurs procédés de préparation
AU2019339777B2 (en) 2018-09-12 2022-09-01 Novartis Ag Antiviral pyridopyrazinedione compounds
KR102188341B1 (ko) 2018-10-24 2020-12-08 하나제약 주식회사 아픽사반의 제조방법
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
EP3753924A1 (fr) * 2019-06-18 2020-12-23 AnaMar AB Nouveaux antagonistes tricycliques 5-ht2
TW202126649A (zh) 2019-09-26 2021-07-16 瑞士商諾華公司 抗病毒吡唑并吡啶酮化合物
IL293592A (en) 2019-12-06 2022-08-01 Vertex Pharma Transduced tetrahydrofurans as sodium channel modulators
US20230271957A1 (en) * 2020-04-09 2023-08-31 Disarm Therapeutics, Inc. Condensed pyrazole derivatives as inhibitors of sarm1
EP4347031A1 (fr) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques
NL2029536B1 (en) 2021-10-27 2023-05-26 Pharma Data S A Apixaban suspension and preparation method
WO2023072967A1 (fr) 2021-10-27 2023-05-04 Pharma-Data S.A. Suspension d'apixaban et procédé de préparation

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3365459A (en) 1964-09-08 1968-01-23 Ciba Geigy Corp Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives
US3340269A (en) 1964-09-08 1967-09-05 Ciba Geigy Corp 1-substituted 4-acyl-2, 3-dioxo-piperidine
US3423414A (en) 1966-01-13 1969-01-21 Ciba Geigy Corp Pyrazolopyridines
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
WO1994020460A1 (fr) 1993-03-11 1994-09-15 Smithkline Beecham Corporation Composes chimiques
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
JPH09511758A (ja) 1994-10-20 1997-11-25 フアイザー・インコーポレイテツド 二環式テトラヒドロピラゾロピリジンおよび医薬としてのその使用
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5939418A (en) 1995-12-21 1999-08-17 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
US5925635A (en) 1996-04-17 1999-07-20 Dupont Pharmaceuticals Company N-(amidinophenyl) cyclourea analogs as factor XA inhibitors
US6057342A (en) 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
US6548512B1 (en) 1996-12-23 2003-04-15 Bristol-Myers Squibb Pharma Company Nitrogen containing heteroaromatics as factor Xa inhibitors
WO1998028282A2 (fr) 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company OXYGENE OU SOUFRE CONTANANT DES HETERO-AROMATIQUES UTILISES COMME INHIBITEURS DU FACTEUR Xa
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
HUP0000735A3 (en) 1996-12-23 2002-03-28 Bristol Myers Squibb Pharma Co Nitrogen containing heteroaromatics as factor xa inhibitors
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
HRP980334A2 (en) 1997-06-19 1999-04-30 Mimi Lifen Quan INHIBITORS OF FACTOR Xa WITH A NEUTRAL P1 SPECIFICITY GROUP
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
WO1998057934A1 (fr) 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company Agents aromatiques a six membres amidino utiles en tant qu'inhibiteurs du facteur xa
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
US6060491A (en) 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
NZ503809A (en) 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
US6271237B1 (en) 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
AU1724499A (en) 1997-12-22 1999-07-12 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
AU3110999A (en) 1998-03-27 1999-10-18 Du Pont Pharmaceuticals Company Disubstituted pyrazolines and triazolines as factor xa inhibitors
PL203771B1 (pl) 1998-07-06 2009-11-30 Bristol Myers Squibb Co Pochodna bifenylosulfonamidu jako dualny antagonista receptorów angiotensyny i endoteliny, sposób jej wytwarzania i jej zastosowanie oraz pochodna bifenylu i pochodna benzenu
US6249205B1 (en) * 1998-11-20 2001-06-19 Steward, Inc. Surface mount inductor with flux gap and related fabrication methods
US6858616B2 (en) 1998-12-23 2005-02-22 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor Xa inhibitors
CA2348740A1 (fr) * 1998-12-23 2000-07-06 Ruth R. Wexler Inhibiteurs de la thrombine ou du facteur xa
FR2787708B1 (fr) * 1998-12-23 2002-09-13 Oreal Procede de teinture mettant en oeuvre un compose a methylene actif et un compose choisi parmi un aldehyde, une cetone, une quinone et un derive de la di-imino-isoindoline ou de la 3-amino-isoindolone
DK1140941T3 (da) 1998-12-23 2005-02-14 Bristol Myers Squibb Pharma Co Nitrogenholdige heterobicykliske forbindelser som faktor Xa-inhibitorer
ES2197092T3 (es) 1999-04-02 2004-01-01 Bristol-Myers Squibb Pharma Company Sulfonil arilos como inhibidores del factor xa.
DE19932813A1 (de) 1999-07-14 2001-01-18 Bayer Ag Substituierte Phenyluracile
JP2004507439A (ja) 1999-07-16 2004-03-11 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー Ｘａ因子阻害剤としての窒素含有ヘテロ二環式化合物
IL148698A0 (en) 1999-09-17 2002-09-12 Cor Therapeutics Inc INHIBITORS OF FACTOR Xa
EP1226123A1 (fr) 1999-11-03 2002-07-31 Du Pont Pharmaceuticals Company Composes cyano utiles en tant qu'inhibiteurs du facteur xa
US6407256B1 (en) 1999-11-03 2002-06-18 Bristol Myers Squibb Co Cyano-pyrrole, cyano-imidazole, cyano-pyrazole, and cyano-triazole compounds as factor Xa inhibitors
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
DK1156569T3 (da) * 2000-05-19 2003-08-18 Usm Holding Ag Kabelføring til modulært møbelsystem
DE10112768A1 (de) * 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
US6960595B2 (en) 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
CA2441772A1 (fr) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1,4,5,6-tetrahydropyrazolo-¬3,4-c|-pyridin-7-ones utilisees comme inhibiteurs du facteur xa
WO2002085356A1 (fr) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1, 4, 5, 6-tetrahydropyrazolo-[3, 4-c]-pyridine-7-ones comme inhiteurs du facteur xa
CA2454632A1 (fr) 2001-07-20 2003-01-30 Compulaw, Llc Procede et appareil de gestion des roles d'auditions
PL204653B1 (pl) 2001-09-21 2010-01-29 Bristol Myers Squibb Co Pochodna pirazolo [3, 4-c] pirydyny, jej zastosowanie i kompozycja farmaceutyczna
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
TW200303201A (en) * 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
EP1505966A4 (fr) 2002-05-10 2006-08-30 Bristol Myers Squibb Co Derives cycloalkyles 1,1-disubstitues utilises en tant qu'inhibiteurs du facteur xa
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US6927187B2 (en) 2003-07-11 2005-08-09 Exxonmobil Chemical Patents Inc. Synthesis of silicoaluminophosphates

Also Published As

Publication number Publication date
NO20083684L (no) 2004-05-03
CY2011016I1 (el) 2017-11-14
NO2011021I1 (no) 2011-09-26
EP1427415A1 (fr) 2004-06-16
SI1427415T1 (sl) 2009-12-31
AU2008207537B2 (en) 2010-11-04
CN104744461A (zh) 2015-07-01
US20050267097A1 (en) 2005-12-01
HU228195B1 (hu) 2013-01-28
LU91888I2 (fr) 2011-12-19
EP1427415A4 (fr) 2005-11-02
CL2008002717A1 (es) 2009-01-09
US8470854B2 (en) 2013-06-25
KR20080075927A (ko) 2008-08-19
US20100119510A1 (en) 2010-05-13
ES2329881T3 (es) 2009-12-02
ME00090B (fr) 2010-10-10
KR100909141B1 (ko) 2009-07-23
PL204653B1 (pl) 2010-01-29
IS8803A (is) 2009-02-26
NO2011021I2 (no) 2012-06-25
KR20040041167A (ko) 2004-05-14
US20080090807A1 (en) 2008-04-17
DK1427415T3 (da) 2009-11-23
US20150210691A1 (en) 2015-07-30
BE2011C034I2 (fr) 2021-11-22
NZ531616A (en) 2006-12-22
JP2005507889A (ja) 2005-03-24
RU2345993C2 (ru) 2009-02-10
ATE439360T1 (de) 2009-08-15
RU2008134413A (ru) 2010-02-27
WO2003026652A1 (fr) 2003-04-03
HRP20040280A2 (en) 2007-09-30
CA2461202A1 (fr) 2003-04-03
UA78232C2 (uk) 2007-03-15
US20110212930A1 (en) 2011-09-01
US20170050964A1 (en) 2017-02-23
IL203533A (en) 2011-12-29
AU2002341693B2 (en) 2008-05-29
HK1061973A1 (en) 2004-10-15
US8188120B2 (en) 2012-05-29
US20200140436A1 (en) 2020-05-07
IL160693A0 (en) 2004-08-31
MEP58108A (en) 2011-05-10
US7531535B2 (en) 2009-05-12
RU2004112191A (ru) 2005-10-10
CN101357914A (zh) 2009-02-04
JP4889705B2 (ja) 2012-03-07
NO328558B1 (no) 2010-03-22
CN1578660A (zh) 2005-02-09
MXPA04002526A (es) 2004-05-31
NO20041163L (no) 2004-05-03
DE60233335D1 (de) 2009-09-24
CA2461202C (fr) 2011-07-12
HUP0402463A2 (hu) 2005-04-28
AR067965A2 (es) 2009-10-28
US7338963B2 (en) 2008-03-04
US20120201816A1 (en) 2012-08-09
AR037092A1 (es) 2004-10-20
MY137830A (en) 2009-03-31
US7960411B2 (en) 2011-06-14
US7691846B2 (en) 2010-04-06
MEP8708A (en) 2010-06-10
US20180244673A1 (en) 2018-08-30
CH1427415H1 (de) 2023-12-21
EP2105436B1 (fr) 2012-02-08
CN102617567A (zh) 2012-08-01
IS2824B (is) 2013-03-15
LU91888I9 (fr) 2019-01-03
RS51444B (sr) 2011-04-30
ZA200402184B (en) 2005-07-27
AU2008207537A1 (en) 2008-09-18
CY1110509T1 (el) 2015-04-29
JP2009079059A (ja) 2009-04-16
IL160693A (en) 2011-06-30
NO2023030I1 (no) 2023-08-17
HUP0402463A3 (en) 2011-07-28
CA2726702A1 (fr) 2003-04-03
US9975891B2 (en) 2018-05-22
CY2011016I2 (el) 2017-11-14
HRP20080382A2 (en) 2008-12-31
EP1427415B1 (fr) 2009-08-12
BR0212726A (pt) 2004-08-03
BRPI0212726B8 (pt) 2021-05-25
IS7184A (is) 2004-03-16
ME00384B (fr) 2011-05-10
HUS1300014I1 (hu) 2017-10-30
EP2105436A1 (fr) 2009-09-30
US20090176758A1 (en) 2009-07-09
US20140113892A1 (en) 2014-04-24
FR11C0042I2 (fr) 2013-01-11
KR100908176B1 (ko) 2009-07-16
DE122011100050I1 (de) 2012-03-15
HRP20040280B1 (hr) 2013-09-30
PT1427415E (pt) 2009-10-29
RS20080517A (en) 2009-07-15
PL204263B1 (pl) 2009-12-31
JP4249621B2 (ja) 2009-04-02
CN110894196A (zh) 2020-03-20
CO5560567A2 (es) 2005-09-30
GEP20074098B (en) 2007-05-10
PL373299A1 (en) 2005-08-22
CN1578660B (zh) 2010-11-24
BRPI0212726B1 (pt) 2015-11-24
LTPA2011012I1 (lt) 2012-07-25
RS20040227A (en) 2006-12-15
ATE544750T1 (de) 2012-02-15
IS3006B (is) 2018-11-15
AU2008207537B8 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
BE2022C531I2 (fr)
BE2022C502I2 (fr)
BE2022C547I2 (fr)
BE2017C055I2 (fr)
BE2017C051I2 (fr)
BE2017C032I2 (fr)
BE2017C050I2 (fr)
LU91888I9 (fr)
BE2007C047I2 (fr)
AU2002307149A8 (fr)
JP2001324958A5 (fr)
JP2002169712A5 (fr)
BRPI0209186B1 (fr)
BRPI0204884A2 (fr)
JP2002245635A5 (fr)
CH1379220H1 (fr)
BE2017C059I2 (fr)
JP2002202905A5 (fr)
JP2001266980A5 (fr)
BRPI0101486B8 (fr)
BRPI0210463A2 (fr)
JP2001274751A5 (fr)
AU2000280389A8 (fr)
JP2002015612A5 (fr)
JP2002248769A5 (fr)